Insider buying is almost always a good signal that a stock is undervalued, as it indicates that the insiders, such as the CEOs, CFOs, and directors, have confidence in the company’s prospects and are willing to invest their own money in it. Insider buying can also provide you with valuable insights into the company’s performance, strategy, and competitive advantage.

In this article, we will look at three stocks that insiders are buying at new highs: Iovance Biotherapeutics (IOVA), Agree Realty (ADC), and Intel (INTC). We will examine their recent insider buying activity, their market positions, and their potential growth opportunities.

Iovance Biotherapeutics (IOVA): A Breakthrough in Cancer Treatment

Iovance Biotherapeutics is a biotechnology company that develops personalized T-cell therapies for solid tumors, especially metastatic melanoma. The company’s flagship product, Amtagvi, is the “first and only one-time, individualized T cell therapy” to receive accelerated approval from the U.S. Food and Drug Administration for a solid tumor cancer.

The company’s stock has soared since its approval announcement, reaching a high of nearly $17 per share in February 2024. Two insiders have also made significant moves in the stock: Director Wayne Rothbaum bought five million shares for about $45.75 million¹, while Director Merrill McPeak bought 250,000 shares for just over $2.287 million.

The company’s impressive clinical results, strong partnerships, and expanding market opportunity make it a compelling stock to watch for investors who are interested in personalized cancer treatment.

Agree Realty (ADC): A Real Estate Investment Trust with High Yield and Insider Buying

Agree Realty is a real estate investment trust (REIT) that focuses on multifamily properties in urban markets. The company offers high-quality tenants, a diversified portfolio, and stable cash flow to its investors.

The company’s stock has been performing well since February 2024, when CEO Joey Agree bought 2,000 shares for $115,120 on the 15th². Since then, he has made two more purchases: 3,500 shares on the 21st for $199,219². The company’s director, John Rakolta Jr., also bought 20,430 shares on the 16th for $1.16 million.

The company’s strong financial performance, attractive valuation, and insider buying indicate that it is a promising stock to consider for investors who are looking for a high-yield REIT with growth potential.

Intel (INTC): A Technology Giant with Insider Buying Confidence

Intel is one of the world’s leading technology companies that produces microprocessors, chipsets, memory solutions, and other hardware products. The company has been facing intense competition from rivals such as AMD and Nvidia in recent years.

However, the company’s CEO, Pat Gelsinger, has been making bold moves to revitalize the company’s fortunes. He joined Intel in November 2023 after leading AMD to become one of the top players in the semiconductor industry. He has also been buying shares of Intel himself: he bought 3,000 shares at an average price of $43.36 each for about $131,100 in February 2024.

The company’s innovative products, strategic partnerships, and insider buying confidence make it a compelling stock to watch for investors who are looking for a technology giant with growth potential.

Conclusion

Insider buying can be a powerful indicator of a stock’s undervaluation and potential growth opportunities. In this article, we looked at three stocks that insiders are buying at new highs: Iovance Biotherapeutics (IOVA), Agree Realty (ADC), and Intel (INTC). We examined their recent insider buying activity, their market positions, and their potential growth opportunities.

If you are interested in learning more about these stocks or other insider trading opportunities, you can visit InvestorPlace or Yahoo Finance for more information.